Physician profile
Chun Lam
NPI 1376839654
$1,082.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $399.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $298.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $227.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $171.97 | 2019-2020 | |
| Horizon Therapeutics Plc | $150.00 | 2020 | |
| Fresenius USA Marketing, INC. | $147.04 | 2019-2020 | |
| Antares Pharma, INC. | $47.62 | 2019-2020 | |
| Baxter Healthcare | $22.46 | 2020 | |
| Amgen INC. | $17.90 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chun Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.